New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:03 EDTCNATConatus initiates emricasan Phase 2b trial
Conatus Pharmaceuticals announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection who have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. The placebo-controlled, double-blind trial is designed to enroll approximately 60 patients at approximately 15 planned U.S. clinical sites. Enrollment is expected to take approximately 12 months. Patients will be randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will then be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. The sponsor-open design may allow for interim data analyses and periodic disclosures on trial progress.
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:19 EDTCNATConatus results at EASL meeting support emricasan registration pathway in NASH
Conatus Pharmaceuticals announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure, or ACLF, and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease, or NAFLD, including the subset of NAFLD patients with nonalcoholic steatohepatitis, or NASH, are addressed in two late-breaker posters. Conatus intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan.
April 15, 2015
17:21 EDTCNATHealthCor reports 5.22% passive stake in Conatus

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use